Cargando…

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma

The role of the immune microenvironment in maintaining disease remission in patients with multiple myeloma (MM) is not well understood. In this study, we comprehensively profile the immune system in patients with newly diagnosed MM receiving continuous lenalidomide maintenance therapy with the aim o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coffey, David G., Maura, Francesco, Gonzalez-Kozlova, Edgar, Diaz-Mejia, J. Javier, Luo, Ping, Zhang, Yong, Xu, Yuexin, Warren, Edus H., Dawson, Travis, Lee, Brian, Xie, Hui, Smith, Eric, Ciardiello, Amanda, Cho, Hearn J., Rahman, Adeeb, Kim-Schulze, Seunghee, Diamond, Benjamin, Lesokhin, Alexander, Kazandjian, Dickran, Pugh, Trevor J., Green, Damian J., Gnjatic, Sacha, Landgren, Ola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475030/ https://www.ncbi.nlm.nih.gov/pubmed/37660077 http://dx.doi.org/10.1038/s41467-023-40966-8

Ejemplares similares

Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
por: Landgren, Ola, et al.
Publicado: (2016)

Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment
por: Hultcrantz, Malin, et al.
Publicado: (2020)

Extreme body mass index and survival in newly diagnosed multiple myeloma patients
por: Shah, Urvi A., et al.
Publicado: (2023)

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
por: Huang, Phoebe A., et al.
Publicado: (2019)

Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities
por: Oben, Bénedith, et al.
Publicado: (2021)

Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies
por: Fatoki, Raleigh Ayoolu, et al.
Publicado: (2022)

Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients
por: Kazandjian, Dickran, et al.
Publicado: (2019)

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
por: Nguyen, Nina, et al.
Publicado: (2022)

Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone
por: Korde, Neha, et al.
Publicado: (2021)

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol
por: Svaton, Michael, et al.
Publicado: (2023)

411 Mrd. €, 11,9 %
por: Kuhn, Joseph
Publicado: (2022)

Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma
por: Pilcher, William, et al.
Publicado: (2023)

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all
por: Kuiper, Roland P., et al.
Publicado: (2021)

Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma
por: Xu, Yuexin, et al.
Publicado: (2019)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)

P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)
por: Askeland, F. B., et al.
Publicado: (2022)

Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer
por: Kazandjian, Dickran, et al.
Publicado: (2016)

Immunophenotype
por: Albani, Salvatore
Publicado: (2014)

Monoclonal gammopathies of clinical significance (MGCS): In pursuit of optimal treatment
por: Oganesyan, Artem, et al.
Publicado: (2022)

P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2
por: Leleu, Xavier, et al.
Publicado: (2023)

Immunophenotyping beyond the limits of time
por: de Graaf, J. Fréderique, et al.
Publicado: (2023)

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
por: Kazandjian, Dickran, et al.
Publicado: (2016)

Ultradeep, targeted sequencing reveals distinct mutations in blood compared to matched bone marrow among patients with multiple myeloma
por: Coffey, David G., et al.
Publicado: (2019)

Leukocyte immunophenotyping: methodological aspects
por: Jämsä, J, et al.
Publicado: (2010)

Mutations in cell elongation genes mreB, mrdA and mrdB suppress the shape defect of RodZ-deficient cells
por: Shiomi, Daisuke, et al.
Publicado: (2013)

MRD Tailored Therapy in AML: What We Have Learned So Far
por: Ngai, Lok Lam, et al.
Publicado: (2021)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
por: Maclachlan, Kylee H., et al.
Publicado: (2021)

MRD in multiple myeloma: more questions than answers?
por: Moreau, Philippe, et al.
Publicado: (2017)

SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?
por: Turcas, Cristina, et al.
Publicado: (2020)

NP-MRD: the Natural Products Magnetic Resonance Database
por: Wishart, David S, et al.
Publicado: (2021)

MRD negativity: considerations for older adults with multiple myeloma
por: Mian, Hira, et al.
Publicado: (2023)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Standardizing Flow Cytometry Immunophenotyping Analysis from the Human ImmunoPhenotyping Consortium
por: Finak, Greg, et al.
Publicado: (2016)

Acute leukemias with unusual immunophenotypes.
por: Park, M. H., et al.
Publicado: (1992)

Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine
por: Overman, M J, et al.
Publicado: (2010)

Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma
por: Xu, Yuexin, et al.
Publicado: (2021)

Microglia immunophenotyping in gliomas
por: Annovazzi, Laura, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_260epplj7b6quatbfah5oitr5d